U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT04822805) titled 'A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma' on March 25.
Brief Summary: This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of anlotinib in treatment of recurrent high-grade glioma.
Study Type: Interventional
Condition: Recurrent High-grade Glioma
Intervention: Drug: Anlotinib hydrochloride
Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
...